Tempest Adds Second In-Vivo CAR-T Approach with Senlang Deal
Tempest gets an exclusive option to license Senlang’s CD7-targeted lentiviral in-vivo CAR-T, now in Phase 1 for relapsed multiple myeloma.
/ 2 items
Tempest gets an exclusive option to license Senlang’s CD7-targeted lentiviral in-vivo CAR-T, now in Phase 1 for relapsed multiple myeloma.
H.C. Wainwright upgrades Tempest Therapeutics to Buy, citing a smart CAR-T acquisition that extends cash runway and strengthens its pipeline.